Showcasing select automated instruments and capabilities at Society for Laboratory Automation and Screening Europe 2022 Conference and Exhibition in Dublin, Ireland
San Jose, Calif., May 24, 2022 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, today introduced five ready-made workcells for Enzyme-linked immunosorbent assay (ELISA) workflows that offer automation capabilities ranging from entry level to advanced. Automating labor-intensive plate-based assays increases walkaway time, throughput, and reproducibility by reducing the amount of common, repetitive, hands-on steps for researchers.
“The pandemic has taught us that walkaway time and automation are critical to keeping labs on track so that scientists can focus on more critical assay development challenges,” said Celeste Glazer, Vice President, Global Marketing and Product Management, Molecular Devices. “The ability to reallocate resources from laborious tasks to more innovative work is critical for accelerating lifesaving research and bringing more therapeutics to market.
“Our new automated ELISA workcells offer five levels of automation, taking the hands-on work out of plate loading and advancing until manual intervention is almost entirely unnecessary. With this approach, we’re leveraging our extensive experience automating workflows to best support scientists wherever they are in their automation journey,” Glazer concluded.
Molecular Devices will feature many components of the ELISA workcells at booth B15 during Society for Laboratory Automation and Screening (SLAS) Europe 2022 Conference and Exhibition in Dublin, Ireland, from May 24-27. The company will also showcase supporting workflow integrations including cell line development and imaging that complements ELISA screening.
While at the show, attendees can connect with subject matter experts on automating their unique research workflows, or explore the latest in automated 3D imaging through the following podium presentation and exhibitor tutorial:
Automation of compound screening high-content imaging analysis of 3D triple-negative breast cancer patient-derived tumoroids on Wednesday, May 25, 2022. Learn how Molecular Devices Senior Scientist Oksana Sirenko, PhD, developed a workcell that enables automated imaging, analysis, and cell culture methods to scale up complex 3D cell-based assays and compound screening.
Novel 3D tissue models, imaging, and automation of organ-on-a-chip assays on Thursday, May 26, 2022. Experts from Molecular Devices and MIMETAS demonstrate how researchers can get powerful new insights from complex biological models by automating culturing, monitoring, and analysis steps of organ-on-a-chip assays.
For a full overview of Molecular Devices’ presence at SLAS, visit this webpage. To learn more about the company’s proven success helping customers automate workflows and advance scientific discovery, visit www.moleculardevices.com.
About Molecular Devices, LLC.
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.